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Abstract. Human induced pluripotent stem cells (hiPSCs) are 
a promising source from which to derive distinct somatic cell 
types for in vitro or clinical use. Existent protocols for hepatic 
differentiation of hiPSCs are primarily based on 2D cultivation 
of the cells. In the present study, the authors investigated the 
generation of hiPSC-derived hepatocyte-like cells using two 
different 3D culture systems: A 3D scaffold-free microspheroid 
culture system and a 3D hollow-fiber perfusion bioreactor. The 
differentiation outcome in these 3D systems was compared 
with that in conventional 2D cultures, using primary human 
hepatocytes as a control. The evaluation was made based on 
specific mRNA expression, protein secretion, antigen expres-
sion and metabolic activity. The expression of α-fetoprotein 
was lower, while cytochrome P450 1A2 or 3A4 activities were 
higher in the 3D culture systems as compared with the 2D 
differentiation system. Cells differentiated in the 3D bioreactor 
showed an increased expression of albumin and hepatocyte 
nuclear factor 4α, as well as secretion of α-1-antitrypsin as 
compared with the 2D differentiation system, suggesting a 
higher degree of maturation. In contrast, the 3D scaffold-free 
microspheroid culture provides an easy and robust method to 
generate spheroids of a defined size for screening applications, 
while the bioreactor culture model provides an instrument for 
complex investigations under physiological-like conditions. 
In conclusion, the present study introduces two 3D culture 
systems for stem cell derived hepatic differentiation each 
demonstrating advantages for individual applications as well 
as benefits in comparison with 2D cultures.
Introduction
The liver represents the central organ for drug metabolism 
and also a main target organ for drug-associated toxicity. 
Therefore, the parenchymal cells of the liver, the hepatocytes, 
are of special interest for pharmacological and toxicological 
investigations.
Primary human hepatocytes (PHH) are considered to 
be the gold standard for such investigations, however their 
availability is limited and their metabolic activity varies, 
primarily due to the mostly unknown genetic backgrounds 
of the donors (1). Primary hepatocytes are also isolated from 
animals, such as rats, but they have a limited predictability 
due to cross-species differences in drug metabolism and 
sensitivity (2). Therefore, the development of in vitro culture 
models using easy accessible cells of human origin is gaining 
increasing scientific interest.
Pluripotent stem cells (PSC) constitute a promising cell 
source for the generation of hepatocytes, due to their capacity to 
differentiate into all cell types of the organism and their ability 
to replicate while maintaining pluripotency. The innovation 
of induced pluripotent stem cell (iPSC) technology opened 
up the possibility of deriving pluripotent cells from different 
donors (3,4) thereby circumventing the ethical concerns 
associated with the use of human embryonic stem cells. Thus, 
pluripotent cell lines with distinct genotypes can be generated, 
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which are of interest in relation to specific disease mecha-
nisms, and to the development of drugs (5,6). These properties 
of PSC in combination with the increasing knowledge of the 
in vivo embryonic development of hepatocytes (7) have led to 
the establishment of several protocols for the in vitro differ-
entiation of PSC into hepatocyte-like cells (HLCs) (8-10). 
Current protocols mimic the different stages of the in vivo 
development of hepatocytes by the sequential addition of 
specific growth factors, like activin A, wnt3a, hepatocyte 
growth factor (HgF) and oncostatin M (OSM) (8,11). Small 
chemical molecules, such as dimethyl sulfoxide (DMSO), 
bromo-indirubin-3'-oxim and SB431542 (12) can be applied as 
well. The generated HLCs demonstrate some characteristics of 
hepatocytes, such as susceptibility to hepatitis C virus infec-
tion (13), secretion of hepatic proteins (14,15) and activity of 
metabolic enzymes (16,17). However, the drug metabolizing 
capabilities of HLCs obtained with current protocols are still 
below those of PHH (18). Recent findings suggested that HLCs 
resemble immature or fetal hepatocytes rather than adult hepa-
tocytes (19,20).
In order to increase the functionality and the maintenance 
of HLCs, the use of extracellular matrices (21,22), transcrip-
tion factor overexpression (23,24) or modified cultivation 
media (25) were suggested. Further approaches focus on 
complex culture systems to provide an organotypic environ-
ment that better approximates the in vivo situation. Cultivation 
of cells in a 3D environment facilitates the formation of physi-
ological cell-cell-contacts, which have been demonstrated to 
be crucial for the preservation of a mature hepatic pheno-
type (26). Different 3D culture systems were investigated for 
hepatic differentiation of PSC, including scaffold-based tech-
nologies (27-29) or scaffold-free culture systems, which rely 
on the self-assembly of the cells (17,30). However, due to the 
lack of standardized methods to characterize the HLCs after 
hepatic differentiation, it is difficult to compare the results 
from different approaches and culture models.
In the present study, the authors investigated the hepatic 
differentiation of human iPSCs (hiPSCs) in two different 
3D culture systems, a scaffold-free microspheroid culture 
system and a 3D hollow-fiber perfusion bioreactor (31). The 
differentiation outcome in these 3D systems was compared 
with that in conventional 2D cultures. All culture systems 
were treated with the same differentiation protocol, allowing a 
comparative analysis of the generated HLCs at mRNA, protein 
and metabolic level. In addition, data from hiPSC-derived 
differentiated cells were compared to those from PHH. Based 
on the results, promising approaches for the development of 
physiologically relevant in vitro liver models were identified.
Materials and methods
Culture of hiPSCs. The generation and characterization of 
the hiPSC line SB Adult3 clone 4 (AD3C4) is described by 
van de Bunt et al (32). The hiPSC lines AD2C3, AD3C1 and 
AD4C1 were generated and characterized in the same way 
from fibroblasts 24245, 23447 and 23801 (Lonza CC-2511, 
tissue acquisition numbers are given; Lonza Group, Ltd., 
Basel, Switzerland), respectively. Cells were seeded on 
culture plates coated with growth-factor-reduced Matrigel 
(Corning Inc., Corning, Ny, USA). For expansion, hiPSCs 
were maintained at 37˚C, 5% CO2 using mTeSR™1 medium 
(Stemcell Technologies, Inc., vancouver, BC, Canada) supple-
mented with 100,000 U/l penicillin and 100 mg/l streptomycin 
(Thermo Fisher Scientific, Inc., Waltham, MA, USA). The cells 
were passaged with 0.5 mM EDTA (Thermo Fisher Scientific, 
Inc.) every 3-5 days, after reaching a confluence of ~70%.
Hepatocyte-like cell dif ferentiation in 2D cultures. 
Differentiation of hiPSCs in 2D monolayer cultures (Fig. 1A) 
was performed according to Szkolnicka et al (11) with minor 
changes. In detail, hiPSCs were plated onto Matrigel-coated [1:20 
diluted in Dulbecco's modified Eagle's medium (DMEM)/F12 
medium] 24-well plates and differentiated into definitive endo-
dermal (DE) cells using the STEMdiff™ Definitive Endoderm 
kit (Stemcell Technologies, Inc.) according to the manu-
facturer's instructions until day 5. From day 5 to 8 cultures 
were maintained in SR-DMSO-Medium [knockout DMEM 
supplemented with 20% knockout serum replacement medium, 
0.5% GlutaMAX, 1% non-essential amino acids, 0.1 mM 
β-mercaptoethanol, DMSO (Sigma-Aldrich; Merck kgaA, 
Darmstadt, Germany) and 1% penicillin/streptomycin]. From 
day 9 on, hepatocyte maturation medium [HepatozyME-SFM, 
1% GlutaMAX, 1% penicillin/streptomycin, 10 µM hydrocor-
tisone 21-hemisuccinate sodium salt (Sigma-Aldrich; Merck 
kgaA), 10 ng/ml human HgF and 20 ng/ml human OSM (both 
from PeproTech EC Ltd., London, Uk)] was used and renewed 
every other day. All reagents were purchased from Thermo 
Fisher Scientific, Inc., if not stated otherwise.
Adaptations for differentiation using 3D microspheroids. For 
the 3D microspheroid differentiation (Fig. 1B), the first steps 
of differentiation were performed in conventional 2D cultures 
using 6-well plates as described above. On day 11 of the differ-
entiation process, the cells were detached enzymatically with 
TrypLE™ (Thermo Fisher Scientific, Inc.) and plated onto low 
attachment 96-well plates. These were prepared by adding 50 µl 
of 60˚C warm 1.5% agarose (Serva Electrophoresis GmbH, 
Heidelberg, Germany)-DMEM/F12 (Thermo Fisher Scientific, 
Inc.) solution into each well of the plate (33). Cells were seeded 
in these 96-well plates at a density of 10,000 cells/well in 150 µl 
of hepatocyte maturation medium. Every other day 100 µl of 
the medium were renewed. The method of spheroid formation 
was proven with additional hiPSC lines, showing the robust 
generation of one spheroid of constant size per well (Fig. 2).
Adaptations for differentiation using perfused 3D bioreactors. 
For hepatic differentiation under dynamic conditions, a hollow-
fiber bioreactor technology was used (Fig. 1C). The bioreactor 
(StemCell Systems gmbH, Berlin, germany) consists of inde-
pendent yet interwoven hollow-fiber capillary systems, which 
serve for counter-current medium perfusion via two medium 
capillary systems and decentralized oxygenation via one gas 
capillary system. The cells are cultured in the extra-capillary 
space (cell compartment) (31). The cell compartment volume 
of the used bioreactors was 2 ml and they were integrated into 
a perfusion circuit (StemCell Systems gmbH) with a total 
volume of 20 ml. Electronic control of system functions was 
provided by a perfusion device (StemCell Systems gmbH) 
that contained two modular pump units, a heating unit and a 
gas-mixing unit.
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Prior to cell inoculation the bioreactors were flushed with 
3 mg Matrigel in 5 ml DMEM/F-12 medium and incubated at 
RT for 1 h. Afterwards, 1x108 hiPSCs were seeded into each 
bioreactor. Cultures were maintained at 37˚C, the medium 
recirculation rate was 10 ml/min and the feed rate was 1 ml/h. 
A mixture of 95% air and 5% CO2 was supplied at a flow rate 
of 20 ml/min. CO2 perfusion rates were adjusted, if required, to 
maintain a stable pH between 7.2 and 7.4. After an adaptation 
phase of two days with mTeSR™1, differentiation of the cells 
was performed with the same media compositions as used for 
2D cultures. After each differentiation step, the culture medium 
was rinsed out by flushing the perfusion circuit with 60 ml of 
the culture medium used in the next differentiation step.
Culture of primary human hepatocytes. PHH were isolated 
from macroscopically healthy tissue from resected human livers 
of patients with informed consent of the patients according 
to the ethical guidelines of the Charité Universitätsmedizin 
Berlin (Berlin, germany). Cell isolation was performed 
according to Pfeiffer et al (34). Hepatocytes were seeded at a 
density of 2.0x105 cells/cm² in 24-well plates (BD Biosciences, 
Franklin Lakes, NJ, USA) coated with rat-tail collagen. Cells were 
cultivated using Heparmed vito 143 supplemented with 0.8 mg/l 
insulin, 5 mg/l transferrin, 0.003 mg/l glucagon, 100,000 U/l 
penicillin and 100 mg/l streptomycin (all from Merck kgaA), 
and 10% FCS (GE Healthcare Life Sciences, Chalfont, UK). 
PHH were either used directly after isolation (PHH 0 h) or after 
24 h of cultivation in 2D culture plates (PHH 24 h).
Glucose and lactate measurements. The metabolic activity of 
the cells was assessed by measuring glucose and lactate concen-
trations with a blood gas analyzer (ABL 700; Radiometer, 
Copenhagen, Denmark).
RNA isolation and reverse transcription-quantitative poly-
merase chain reaction (RT-qPCR). Total RNA was isolated 
using TRIzol™ (Thermo Fisher Scientific, Inc.), following the 
manufacturer's instructions. The High Capacity cDNA reverse 
transcription kit (Applied Biosystems; Thermo Fisher Scientific, 
Inc.) was used to convert 1 µg of RNA to cDNA following the 
manufacturer's instructions. The quantitative validation of the 
expression of selected genes was performed by RT-qPCR, as 
previously described (35). In detail, the Applied Biosystems 
StepOne real-time PCR system was applied using custom 
PrimerDesign primers (Primerdesign Ltd., Chandler's Ford, 
Uk) and the SyBR-green PCR master mix (cat. no. 4368577; 
Applied Biosystems; Thermo Fisher Scientific, Inc.), following 
the manufacturer's instructions. Primers are listed in Table I. 
Reactions were run in triplicate on a StepOne Plus instrument 
(Applied Biosystems; Thermo Fisher Scientific, Inc.). Running 
conditions were: 95˚C for 10 min, followed by 40 cycles of 95˚C 
for 15 sec and 60˚C for 60 sec.
Data from RT-qPCR were normalized to multiple internal 
control genes (18S, EIF 2A4, β-actin and SDHA) with the 
geNorm algorithm as described by vandesompele et al (36). 
Results are presented as fold-changes in gene expression 
relative to 2D cultures on day 18 calculated with the ΔΔCq 
method (37).
Enzyme-linked immunosorbent assay (ELISA). Cell culture 
supernatants were clarified by centrifugation and stored at 
-20˚C until assayed. The secretion of α-fetoprotein (AFP), 
Figure 1. Cultivation systems used for hepatic differentiation of hiPSCs. (A) In the 2D monolayer culture, hiPSCs were differentiated on Matrigel coated 
24-well plates. (B) In the 3D scaffold-free microspheroid culture cells were cultivated in 96-well plates. within one well of the plate, one microspheroid was 
generated by self-aggregation of differentiating cells on top of a low attachment surface coated with agarose. (C) In the 3D hollow fiber bioreactor, hiPSCs 
were differentiated in the extra-capillary space of the bioreactor. The three capillary systems supply medium (blue and red) and oxygen (grey). The capillaries 
were coated with Matrigel on the extra-capillary-side to allow cell attachment. hiPSCs, human induced pluripotent stem cells.
Figure 2. Microspheroids derived from three different human induced pluripotent stem cell lines at day 18.
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albumin (ALB) and α-1-antitrypsin (A1AT) was quantified 
with an ELISA, using the antibodies provided in Table II and 
the protocol as described by Liu et al (38). ELISA plates were 
read at 490 nm with a reference wavelength of 630 nm using 
a MRX II plate reader (Dynex Technologies, Chantilly, VA, 
USA) and the concentration of the appropriate protein in each 
sample was calculated from standard curves using MRX II 
Endpoint software 2.02 (Dynex Technologies).
Urea analysis. Cell culture supernatants were clarified 
by centrifugation and stored at -20˚C until assayed. Urea 
was measured in the cell culture supernatant without any 
additional treatment, using the QuantiChrom™ Urea assay 
kit (DIUR-500; BioAssay Systems, Hayward, CA, USA) 
according to the manufacturer's instructions.
Immunofluorescence analysis. The 2D cultures were fixed in 
4% paraformaldehyde (PFA; Electron Microscopy Science, 
Hatfield, PA, USA) in phosphate-buffered saline (PBS) at room 
temperature for 10 min. Primary and secondary antibodies 
were applied in PBS with 0.5% Triton X-100 and 1% BSA 
(both from Sigma-Aldrich; Merck KGaA) and incubated at 4˚C 
overnight or at room temperature for 1.5 h, respectively. All 
primary and secondary antibodies are provided in Table III. 
Finally, a nuclear counter stain was performed with 0.8 µg/ml 
Hoechst 33342 (Thermo Fisher Scientific, Inc.) in PBS at room 
temperature for 30 min. The quantification of immunoreactive 
cells was performed with the Cellomics Array Scan vTi and 
Cellomics Scan and view Software (version 6.3.1) (both from 
Thermo Fisher Scientific, Inc.).
The microspheroids were collected in a 1.5 ml reaction 
tube and fixed in 4% PFA (Electron Microscopy Science) 
in PBS at 4˚C overnight. An ~60˚C warm 2% agarose solu-
tion in PBS was prepared, added to the microspheroids and 
centrifuged at 20,000 x g for 1 sec. The resulting agarose plug 
was dehydrated in a tissue processor (Tissue-Tek vIP; Sakura 
Finetek Europe B.v., Flemingweg, The Netherlands), paraf-
finized and cut into slides of 4.0 µm thickness.
For immunohistochemical staining of the bioreactor 
cultures the hollow-fiber bed was excised en bloc, fixed with 
4% formaldehyde solution (Herbeta Arzneimittel Detlef 
karlowski e.k., Berlin, germany) at room temperature for 1 h, 
dehydrated, paraffinized and cut into slides of 4.0 µm thickness.
Paraffin sections were rehydrated and boiled in 10 mM 
citrate buffer (pH 6.0) for 12 min. Pre-blocking was performed 
with PBS containing 0.5% Triton X-100 and 1% BSA at room 
temperature for 1 h. Antibody staining was performed as 
described above. The primary and secondary antibodies used are 
Table I. Primer sequences for the custom real-time PCR (Primerdesign Ltd.).
gene gene Forward primer Reverse primer Amplicon
symbol name 5'→3' sequence 3'→5' sequence size (bp)
AFP α-fetoprotein CAgTAATTCTAAgAgTTgCTAAAggAT CCTggATgTATTTCTgTAATTCTTCTT 117
AHR Aryl hydrocarbon AATTTTgACCCTggTTTTTggATT TggTTTggAATAATTgTgAATAgCA 129
 receptor
ALB Albumin TgACAAATCACTTCATACCCTTTTT gCATTCATTTCTCTCAggTTCTTg 118
CXCR4 C-X-C motif CCAAAGAAGGATATAATGAAGTCACT GGGCTAAGGGCACAAGAGA 88
 chemokine
 receptor 4
CYP1A2 Cytochrome P450 gCCTTCATCCTggAgACCTT TCAgCgTTgTgTCCCTTgT 82
 family 1
 subfamily A
 member 2
CYP3A4 Cytochrome P450 ACCgTAAgTggAgCCTgAAT AAgTAATTTgAggTCTCTggTgTT 90
 family 3
 subfamily A
 member 4
CYP3A7 Cytochrome P450 AgAgAgATAAggAAggAAAgTAgTgA TgTgTACgggTTCCATATAgATAgA 114
 family 3
 subfamily A
 member 7
HNF4A Hepatocyte gACCTCTACTgCCTTggACAA gATgAAgTCgggggTTggA 87
 nuclear factor 4α
NANOG Nanog homeobox gCTgTgTgTACTCAATgATAgATTT gAggTTCAggATgTTggAgAg 85
SOX9 SRy-box 9 ggACCAgTACCCgCACTTg AATCCgggTggTCCTTCTTg 143
SOX17 SRy-box 17 gTAgAAggggATgTCCAAgTAAT TgTgAAgATTAAggTAAACTgAATgT 144
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detailed in Table III. Finally, the cells were embedded in Roti-
Mount FluorCare DAPI (Carl Roth gmbH + Co. kg, karlsruhe, 
germany). The quantification of marker positive cells was 
performed with the Opera Phenix and the Harmony software 
(version 4.1) (both from PerkinElmer, Inc., waltham, MA, USA).
Cytochrome P450 (CYP) analysis. CYP iso-enzyme activi-
ties were analyzed based on assays established in previous 
studies (39,40). A substrate mix containing midazolam, phen-
acetin and bupropion was prepared in the respective culture 
medium without pretreatment for induction. Details of the 
Table II. Antibodies used for analysis of hepatic export proteins using ELISA.
Species and antigen name Type Target Provider, catalog no. Dilution
Rabbit anti-albumin (capture antibody) Polyclonal Anti-human Agilent Technologies,  1:1,000
   Inc., A0001
Mouse anti-albumin antibody (intermediate antibody) Monoclonal Anti-human Sigma-Aldrich, A6684 1:1,000
Rabbit anti-Iggs, HRP conjugated (detection antibody) Polyclonal Anti-mouse Agilent Technologies, 1:1,000
   Inc., P0260
Rabbit anti-AFP (capture antibody) Polyclonal Anti-human Agilent Technologies, 1:2,000
   Inc., A0008
Rabbit anti-AFP, HRP conjugated (detection antibody) Polyclonal Anti-human Agilent Technologies, 1:2,500
   Inc., P0128
Sheep anti-A1AT, HRP conjugated (detection antibody) Polyclonal Anti-human Abcam, ab 8768 1:1,500
Agilent Technologies, Inc.; Sigma-Aldrich; Merck KGaA; Abcam, Cambridge, UK. ELISA, enzyme-linked immunosorbent assay; AFP, α-fetoprotein.
Table III. Primary and secondary antibodies used for immunofluorescence analysis.
Species and antigen name Type Target Provider, catalog no. Dilution
Mouse anti-α-fetoprotein Monoclonal Anti-human Thermo Fisher Scientific, Inc.,  1:1,000
   180003
Mouse anti-cytokeratin 18 Monoclonal Anti-human Santa Cruz Biotechnology, Inc.,  1:100
   sc-6259
Rabbit anti-albumin Polyclonal Anti-human Dako Cytomation, A0001 1:2,000
Rabbit anti-hepatocyte nuclear factor 4α Polyclonal Anti-human Santa Cruz, sc-8987 1:100
A488 goat anti-mouse Polyclonal Anti-mouse Thermo Fisher Scientific, Inc.,  1:500
   A11029
A594 goat anti-rabbit Polyclonal Anti-rabbit Thermo Fisher Scientific, Inc.,  1:500
   A11037
Thermo Fisher Scientific, Inc.; Santa Cruz Biotechnology, Inc., Dallas, TX, USA.
Table IV. Applied substrates and their corresponding CYP isoenzymes with resulting products and applied concentrations.
 Corresponding  Final  Recorded
Substrate CYP isoenzyme Provider concentration Solutions for elution transitions
Midazolam CYP3A4/5 Roche 25 µM Double distilled water containing 0.1% 1'-Hydroxymidazolam
  Diagnostics  formic acid and acetonitrile 342.1-324.0 m/z
  GmbH  containing 0.1% formic acid
Phenacetin CYP1A2 Sigma-Aldrich 200 µM Double distilled water containing Paracetamol 
    0.1% formic acid and methanol 152.1-110.1 m/z
    containing 0.1% formic acid
Bupropion CYP2B6 Sigma-Aldrich 75 µM Double distilled water containing Hydroxybupropion
    0.1% formic acid and methanol 256.1-238.1 m/z
    containing 0.1% formic acid
Roche Diagnostics GmbH, Basel, Switzerland; Sigma-Aldrich; Merck KGaA.
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used substrates, their final concentrations and information 
on the LC-MS analysis are provided in Table Iv. A medium 
blank was used for normalization. In 2D cultures, the assay 
was performed on four wells of a 24-well plate and the super-
natants were pooled per time-point. In microspheroids, the 
assay was performed in 8 wells of a 96-well plate by collecting 
~10 microspheroids/well. Supernatants of the wells were 
pooled per time-point. For the bioreactors, 1 ml of a 20-fold 
concentrated substrate mix was applied to the bioreactor 
system. For all culture systems, samples were taken after 0, 
1, 2 and 6 h.
The supernatants were diluted with quench solution 
(20% methanol or acetonitrile with 0.1% formic acid) containing 
the stable isotope-labeled metabolite as an internal standard. 
LC-MS analysis was performed using the following equip-
ment: HTS-xt PAL autosampler (CTC Analytics Ag, zwingen, 
Switzerland), 1290 infinity G4220A binary pump and degasser 
(Agilent Technologies, Inc., Santa Clara, CA, USA), MistraSwitch 
column oven (Maylab Analytical Instruments gmbH, vienna, 
Austria) and a YMC C18 Triart, 30x2 mm, 1.9 µm (YMC Europe 
gmbH, Dinslaken, germany) column. All ion chromatograms 
were recorded on a 6500 Triple Quad (QqQ) LC-MS/MS-system 
hybrid mass spectrometer (AB Sciex Pte, Concord, ON, Canada) 
equipped with an Iondrive™ Turbo v ion source operated in the 
positive electrospray ionization mode. Integration of chromato-
grams as well as determination of peak areas was performed by 
Analyst software version 1.6.2 (Applied Biosystems/MDS Sciex).
DNA isolation. RLT buffer (Qiagen gmbH, Hilden, germany) 
was added to a defined number of wells, number of micro-
spheroids or volume of the cell compartment of bioreactors. 
The DNA was isolated from the cell extracts by use of the 
QIAamp DNA micro kit (Qiagen gmbH) according to the 
manufacturer's protocol.
Statistical analysis. Data evaluation and graphical illustration 
were performed with graphPad Prism 5.0 and 7.0 (graphPad 
Software, Inc., San Diego, CA, USA). Experiments were 
performed in triplicate, unless stated otherwise, and results 
are presented as median ± interquartile range. Data for energy 
metabolism and secretion of proteins were normalized to the 
initial cell number and area under curve (AUC) was calculated. 
Data for CYP activities were normalized against the DNA 
content at day 18. Differences between the different culture 
systems or to PHH were detected applying the Mann-whitney 
test or the unpaired, two-tailed t-test.
Results
Differentiation of hiPSCs to HLCs. The hiPSC line AD3C4 
was selected from different previously tested hiPSC lines 
generated within the StemBANCC consortium. The compara-
tive study of a 2D cell culture differentiation system (Fig. 1A) 
with a 3D scaffold-free microspheroid system (Fig. 1B) and a 
perfused 3D hollow-fiber bioreactor (Fig. 1C) was performed 
using three independent batches of AD3C4 hiPSCs at the same 
passage number. To compare the different culture systems, 
mRNA levels and secretion of stage specific markers as well 
as immunohistochemical staining and CyP activity were 
analyzed (Fig. 3).
Energy metabolism. In order to evaluate the energy metabolism 
during hepatic differentiation of hiPSCs, the glucose consump-
tion rates and lactate production rates were determined at the 
time of medium exchange (2D culture, microspheroids) or 
daily (bioreactor). glucose consumption and lactate produc-
tion rates increased in 2D cultures and microspheroids 
during the first 6 days of differentiation. Following this, 
rates continuously declined in both culture systems during 
the whole differentiation period (Fig. 4A). The bioreactor 
cultures showed a slight increase of glucose consumption and 
lactate production rates during the first 2 days of differen-
tiation and afterwards also a continuous but slight decrease 
until the end of hepatic differentiation. At the end of differ-
entiation, these values were comparable to 2D cultures and 
microspheroids (Fig. 4A). The AUC for glucose consumption 
was significantly higher in 2D cultures and microspheroids 
compared with bioreactors (p<0.0001). The time course of 
lactate production mirrored that of glucose consumption and 
the AUC for lactate production was also significantly higher 
Figure 3. Comparative analyses of three cultivation systems for hepatic differentiation of hiPSCs. The cells were differentiated into HLCs by the use of a 
2D monolayer culture, a 3D scaffold-free microspheroid culture and a 3D hollow fibre bioreactor. For all systems identical differentiation media were used 
as indicated. Analyses of glucose consumption/lactate production (gluc/Lac), mRNA expression (RNA), secretion of proteins (sec. protein), urea produc-
tion (Urea), intracellular protein expression (protein) and metabolism of substrates by cytochrome P450 isoenzymes (CYP-Metab.) were performed at the 
indicated days. hiPSCs, human induced pluripotent stem cells; HLCs, hepatocyte-like cells.
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in 2D cultures and microspheroids compared with bioreactors 
(p<0.0001) (Fig. 4B)
Gene expression profiling of hiPSC-derived HLCs. To 
evaluate the maturation state of the HLCs obtained in the 
different culture systems compared to freshly isolated and 
cultured PHH, the mRNA expression of stage-specific genes 
was analyzed and calculated in relation to 2D differentiated 
HLCs at day 18. The expression of the pluripotency-associated 
homeobox gene Nanog (NANOg) was downregulated in HLC 
relative to undifferentiated hiPSCs, irrespective of the culture 
system (Fig. 5A). within the HLC and PHH groups, the 2D 
differentiated HLCs expressed the highest amount of NANOG. 
The DE markers SRy-box 17 (SOX17) and C-X-C motif chemo-
kine receptor 4 (CXCR4) peaked at day 5 in 2D cultures and 
showed subsequently a downregulation (Fig. 5B and C). The 
significantly higher expression of AFP in the HLCs compared 
to cultured PHH (p<0.0001) demonstrated the immature 
properties of the in vitro generated cells. within the in vitro 
generated cells, the 2D HLCs displayed a significantly higher 
expression of AFP compared to HLCs derived in the bioreactor 
(p=0.0477), and a higher, although not significant, expres-
sion than the microspheroids. There was also a significantly 
lower AFP expression in cultured PHH compared to freshly 
isolated PHH (p=0.032) (Fig. 5D). The cholangiocyte marker 
SRy-box 9 (SOX9) showed the highest expression in HLCs 
from 2D cultures and bioreactors (Fig. 5E). Microspheroids 
and cultured PHH expressed significantly lower amounts of 
SOX9. Expression of the hepatocyte marker ALB was highest 
in freshly isolated PHH and showed a significant drop after 
24 h of cultivation (p=0.0028) (Fig. 5F). HLCs derived in the 
bioreactor expressed ALB at a higher amount compared to 
2D HLCs and microspheroids indicating a higher degree of 
maturation in the bioreactor system. The expression of hepa-
tocyte nuclear factor 4α (HNF4A) was significantly higher in 
HLCs as compared to cultured PHH (p≤0.0003) (Fig. 5G). 
Among the HLCs, cells derived in the bioreactor expressed 
significantly more HNF4A than cells generated in 2D or in 
microspheroids (p≤0.0059). Furthermore, there was a signifi-
cant drop of HNF4A expression in cultured PHH compared 
to freshly isolated PHH (p≤0.0001). Regarding the expression 
of metabolic enzymes, the CYP3A4 expression presented a 
significant decrease from freshly isolated PHH to cultured 
PHH and a further decrease from cultured PHH to all in vitro 
generated HLCs (p≤0.0142) (Fig. 5H). The highest CYP3A7 
expression among the HLCs could be detected in the bioreactor 
system. There was again a significant decrease of CYP3A7 
expression from freshly isolated PHH to PHH cultured over 
24 h (p<0.0001) (Fig. 5I). CYP1A2 indicated only a marginal 
expression in HLCs in all culture systems. In contrast, freshly 
isolated PHH demonstrated a high expression, which however 
significantly decreased within 24 h of cultivation (Fig. 5J). 
The nuclear receptor aryl hydrocarbon receptor (AHR) was 
expressed in the in vitro systems at levels positioned between 
freshly isolated PHH (high expression) and cultivated PHH 
(low expression) (Fig. 5k). In conclusion, among the in vitro 
systems the bioreactor system showed the highest matura-
tion stage on mRNA expression level, but was still lower as 
compared to freshly isolated PHH.
Secretion of hepatic proteins and metabolites by HLCs. The 
detection of secreted hepatic proteins allows an estimation 
of the differentiation status of the cells over time. The secre-
tion of AFP increased in all culture systems from day 9 until 
day 13 and subsequently decreased until day 18 reaching 
basal levels (Fig. 6A). Secretion of ALB and A1AT could be 
detected only in the bioreactors from differentiation day 9 and 
11 onwards, respectively (Fig. 6B and C). Urea production was 
significantly higher in the microspheroids than in 2D cultures 
(p=0.0027) or bioreactors (p=0.0022) and peaked at day 13 
of differentiation (Fig. 6D). However, the strong production of 
urea decreased subsequently to a lower level as compared to 
the 2D cultures and bioreactors, which produced a constant 
level of urea from day 11 onwards (Fig. 6D). Compared to the 
2D cultures, cells in the bioreactor produced significantly less 
urea (p=0.0021).
Immunohistochemical characterization of HLCs. Immuno-
histochemical analysis of liver-specific markers was 
performed to characterize the cell composition in the different 
culture systems at day 18 (Fig. 7A-C). The hepatocyte marker 
HNF4A was detectable in half of the cells in the 2D cultures, 
whereas this proportion was lower in the microspheroids 
and bioreactors (Fig. 7D-F and J). A shift from the nuclear 
Figure 4. Energy metabolism of hiPSCs during hepatic differentiation in 2D cultures (2D, circles), MS (squares) or BR (triangles). (A) glucose consumption 
and (B) lactate production are shown. Areas under curve were calculated for each dataset and differences between groups were determined with the unpaired, 
two-tailed t-test. P-values <0.1 are given in the graphs (2D cultures: n=6; microspheroids and bioreactors: n=3, median of biological replicates ± interquartile 
range). MS, microspheroids; BR, bioreactors; hiPSCs, human induced pluripotent stem cells.
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staining to a diffuse cytoplasmic and weak nuclear staining 
was obvious, implying a possible downregulation of HNF4A. 
In contrast, cytokeratin 18 (Ck18) was detectable at similar 
levels in all culture systems (Fig. 7D-F and k). The fetal 
Figure 5. gene expression of hiPSC derived hepatocyte-like cells in 2D cultures, microspheroids, bioreactors or in PHH. The mRNA expression of (A) NANOG, 
(B) SOX17, (C) CXCR4, (D) AFP, (E) SOX9, (F) ALB, (g) HNF4A, (H) CYP3A4, (I) CYP3A7, (J) CYP1A2 and (k) AHR is shown. Samples for expression 
analysis were taken before (hiPSC day 0) and after hepatic differentiation of hiPSC in 2D cultures (2D day 18), microspheroids (MS day 18) or bioreactors 
(BR day 18). In addition, samples were taken after definitive endodermal differentiation in 2D cultures (2D day 5). Further, mRNA samples from freshly 
isolated (0 h) or 2D cultured PHH (24 h) were used for expression analyses. Differences in gene expression between groups were calculated using the 
Mann-whitney test. Data from day 0 and 5 were not included in comparative statistics because the aim was to compare the different culture systems among 
each other and to the current ‘gold-standard’, the cultured PHH. p<0.1 are given in the graphs [median and data points of 3 resp. 6 (for 2D cultures) independent 
experiments plus technical replicates (three per experiment) are shown]. hiPSC, human induced pluripotent stem cells; PHH, primary human hepatocytes; 
MS, microspheroids; BR, bioreactors; NANOG, Nanog homeobox; SOX17, SRY-box 17; CXCR4, C-X-C motif chemokine receptor 4; AFP, α-fetoprotein; 
SOX9, SRY-box 9; ALB, albumin; HNF4A, hepatocyte nuclear factor 4α; CyP3A4, cytochrome P450 family 3 subfamily A member 4; CyP3A7, cytochrome 
P450 family 3 subfamily A member 7; CyP1A2, cytochrome P450 family 1 subfamily A member 2; AHR, aryl hydrocarbon receptor; d, day.
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hepatic marker AFP was present in three quarters of the 
cells in the 2D culture system, which was significantly 
higher compared to the microspheroids (p<0.0001) and the 
bioreactors (p=0.0004 (Fig. 7g-I and L). The number of 
ALB-positive cells was significantly higher in 2D cultures 
(p=0.0017) and bioreactors (p=0.0476) compared with micro-
spheroids (Fig. 7g-I and M). Cells double-positive for AFP 
and ALB, which indicate a transition from fetal-like to mature 
hepatocytes, were present in all in vitro culture systems, with 
a significant lower amount in microspheroids compared to 
2D cultures (p=0.0254) (Fig. 7N). In addition, the immu-
nohistochemical analysis revealed an irregular distribution 
of cells positive for HNF4A or ALB in 3D culture systems. 
Furthermore, the microspheroids showed a decrease in size 
with increasing culture time and holes could be detected 
within the spheroids and in the aggregates from the bioreactor 
at day 18.
CYP3A4 activity of HLCs in different culture systems. 
The basal capacity of CyP-dependent drug metabolism 
was examined in the HLC cultures by the application of 
substrates for CyP1A2 (phenacetin), CyP2B6 (bupropion) 
and CYP3A4/5 (midazolam). Activity of CYP2B6 could not 
be detected in HLCs irrespective of the cultivation system 
(data not shown). Data, normalized against the DNA content, 
measured at the day of the CyP analysis, showed a turnover 
of phenacetin in the linear range of the quantification method 
only for HLCs from the bioreactor and in PHH 2D-cultured 
for 24 h (Fig. 8A). In comparison to PHH the CyP1A2 
activity of HLCs was ~5 times lower in the bioreactor and 
not detectable in 2D cultures and 3D microspheroids, which 
is in line with the finding of marginal mRNA expression of 
CYP1A2 (Fig. 5J). Activity of CyP3A4/5 was detectable in 
all HLC samples, but also in undifferentiated hiPSCs and 
PHH (Fig. 8B) which corresponds to the mRNA expres-
sion data (Fig. 5J). The CyP3A4/5 activity of PHH was 
significantly higher compared to all HLC culture systems 
(p≤0.0007). Cells obtained in the microspheroids had a 
slightly higher activity compared to the bioreactors and the 
2D cultures. The lowest activity was detectable in the undif-
ferentiated hiPSCs.
Discussion
Human iPS cells are of interest as a source for human hepato-
cytes including their possible use in pharmacological analyses 
and toxicity testing, ideally to gain sophisticated data in vitro. 
To date hiPSC-derived hepatocytes still show an immature 
phenotype and lack the functional range of their in vivo coun-
terparts (19,20). In the present study, the propensity of two 
different 3D culture systems to enhance hepatic maturation 
of hiPSCs was investigated: i) Scaffold-free microspheroids 
based on the self-aggregation of pre-differentiated cells, 
and ii) a hollow-fiber bioreactor based on interwoven capil-
lary systems, which form an adhesion scaffold for the cells 
residing in the extra-capillary space. The compared culture 
systems differ in their culture characteristics, for example in 
the bioreactor, cells are supplied with nutrients and oxygen 
via perfusion, and mass exchange is mainly influenced by 
perfusion rates and substance properties. In contrast, micro-
Figure 6. Secretion of specific proteins and metabolites by hiPSCs during hepatic differentiation in 2D cultures (2D, circles), MS (squares) or bioreactors 
(BR, triangles). (A) Secretion of AFP, (B) albumin (ALB), (C) A1AT and (D) urea is shown. Values are normalized to 106 initial cells on day 0 (2D cultures 
and bioreactors) or day 11 (microspheroids). Areas under curve were calculated for each dataset and differences between groups were determined with the 
unpaired, two-tailed t-test (2D cultures: n=6; microspheroids and bioreactors: n=3, median of biological replicates ± interquartile range). MS, microspheroids; 
BR, bioreactors; AFT, α-fetoprotein; A1AT, α-1-antitrypsin; hiPSCs, human induced pluripotent stem cells.
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spheroids are maintained under static conditions and their size 
influences the supply of oxygen and nutrients to the center of 
the 3D cell aggregates. However, both 3D cultivation systems 
may support the formation of an in vivo like cell-cell interac-
tion and microenvironment as already shown for PHH (41,42).
To evaluate the differentiation process and the maturation 
state of the obtained cells, metabolic parameters, secretion and 
expression of stage-specific markers, as well as CYP enzyme 
activities, were analyzed in comparison to 2D cultures, using 
freshly isolated or cultured PHH as controls.
Since the bioreactors and the microspheroids do not allow 
microscopic analysis on a cellular level of the cells during 
culture, alternative read outs were used to monitor the differ-
entiation process. Therefore, glucose consumption and lactate 
production were analyzed to evaluate the metabolic activity of 
hiPSCs in the different culture systems over time. The high rate 
of glucose consumption and lactate production at the begin-
ning of differentiation in all systems is in consistence with the 
known glycolytic state of undifferentiated hiPSCs (43). with 
increasing length of culture, both rates decreased in all culture 
systems which could be explained either by a decreased cell 
proliferation or by a shift to oxidative phosphorylation as an 
energy source in association with cell differentiation (43).
The finding of cell differentiation is also supported by the 
observed downregulation of the pluripotency marker NANOG, 
a temporal peak of DE markers and an upregulation of hepatic 
Figure 7. Expression of liver-specific immunohistochemical markers in human induced pluripotent stem cell-derived hepatocyte-like cells in 2D cultures 
(2D day 18), MS (day 18) or BR (day 18). (A-C) Bright-field images of the three culture systems at the day of analysis. (D-N) Expression of (D-F and J) 
HNF4A, (D-F and K) cytokeratin 18, (G-I, L and N) AFP and (G-I, M and N) ALB was determined by quantitative analysis of immunofluorescence pictures. 
Differences between groups were determined with the unpaired, two-tailed t-test (2D cultures: n=6; MS and BR: n=3, median of biological replicates ± inter-
quartile range). p<0.1 are given in the graphs. Scale bars correspond to 100 µm. d, day; MS, microspheroids; BR, bioreactors; HNF4A, hepatocyte nuclear 
factor 4α; Ck18, cytokeratin 18; AFP, α-fetoprotein; ALB, albumin.
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markers on mRNA level, although the extent of downregula-
tion and upregulation varied between the compared culture 
systems. For example, the mRNA expression of the hepatic 
markers ALB, CYP3A4 and HNF4A [important for the activa-
tion of CYP3A4 (44)] was significantly higher in bioreactors 
compared to 2D cultures, indicating a more mature state of the 
HLCs in the bioreactors. Moreover, expression of SOX9, which 
is weakly expressed in hepatoblasts and strongly in cholangio-
cytes (45) was observed in 2D cultures and bioreactors and 
was even higher than in freshly isolated PHH. This finding 
can be explained by the generation of cholangiocytes in these 
two differentiation systems in accordance to observations by 
Freyer et al (39) and Miki et al (46). Another explanation for 
the detected SOX9 expression may be the presence of bipotent 
progenitors (hepatoblasts) in the differentiated cell popula-
tions. This assumption is supported by De Assuncao et al (47), 
who developed a protocol for cholangiocyte differentiation 
from hiPSCs and observed an increase in cholangiocyte 
markers already during the hepatic progenitor phase. AFP 
expression was still significantly higher in HLCs than in PHH, 
although the 3D culture systems demonstrated a significant 
downregulation compared to the 2D culture. The downregula-
tion of AFP expression during hepatic maturation has been 
challenging in hepatic differentiation protocols (17,22). The 
significant decrease of mRNA expression levels of hepatic 
markers such as ALB, HNF4A and CYP3A4 in cultured PHH 
compared to freshly isolated PHH underlines again the impor-
tance of appropriate culture models to maintain the hepatic 
phenotype. Additionally, it demonstrates the difficulty to get 
standardized controls for hepatic differentiation approaches.
The finding of a more mature state of HLCs in bioreactors 
as compared with the other culture systems under investigation 
is supported by the detection of ALB and A1AT protein secre-
tion solely in the culture perfusate of the bioreactors. However, it 
cannot be excluded that the absence of ALB and A1AT detection 
in the microspheroids and in 2D cultures is due to the low ratio of 
cell number to culture volume in 2D cultures (0.4x106 cells/ml) 
and in microspheroids (0.07x106 cells/ml) as compared with a 
ratio of 5x106 cells/ml in the bioreactors. Thus, the measured 
parameters are much more diluted in 2D cultures and in 
microspheroids than in the bioreactor system, and thus ALB 
and A1AT may be under the detection limit. This underlines 
another characteristic of the bioreactor system, which enables 
high-density culture of the differentiated cells. An exception to 
this observation was the high peak in urea secretion detected for 
microspheroids on day 13. This may be explained by the fact that 
the HLCs were subjected to cell stress during enzymatic detach-
ment and cell reseeding for microspheroid formation on day 11. 
This is in line with findings from studies using PHH, which 
also showed a peak for urea secretion at the first day in culture 
together with a high enzyme release, which was attributed to cell 
stress during the preceding isolation procedure (40,48).
The results from protein secretion are in line with the 
analysis of the marker expression by immunohistochemistry 
showing the highest ratio of ALB to AFP positive cells in the 
bioreactors. In contrast, the amount of HNF4A positive cells 
was highest in 2D cultures whereas for Ck18 positive cells 
no distinct differences between the culture systems could be 
detected. In addition, immunohistochemical analysis of the 
3D cell aggregates in microspheroids and bioreactors revealed 
a heterogeneous cell population which may be a result of 
gradient formation of differentiation promoting factors since 
it has been reported that concentration gradients influence cell 
differentiation and tissue formation (49,50).
The basal metabolic activity of CyP1A2 and CyP3A4 of 
the in vitro generated cells was distinctly lower as compared 
to PHH. However, cells in the 3D systems displayed a higher 
CyP-functionality than 2D cultures, in line with previous 
studies showing increased CyP activities of PSC-derived 
hepatocytes in 3D models compared to 2D cultures (27,29,51). 
However, for pharmacological and toxicological applications 
of hiPSC-derived HLCs, a further increase of basal CyP 
activities would be desirable to approximate the functionality 
of PHH as the current gold standard for in vitro drug testing. 
The authors focused on basal CyP activities, since application 
for pharmacological and toxicological studies may require the 
opportunity to detect an induction by the test-compound, which 
may be masked by the routine use of an inducer (e.g. rifampin). 
Figure 8. Activities of different cytochrome P450 (CYP) isoenzymes in 
hiPSC-derived hepatocyte-like cells in 2D cultures on day 18 (2D day 18), 
MS on day 18 (MS day 18), BR on day 18 (BR day 18), in undifferentiated 
hiPSCs on day 0 (hiPSC day 0) or in PHH 24 h after seeding. CyP activities 
were determined by measuring the formation of (A) acetaminophen from 
phenacetin via CYP1A2 and (B) the formation of 1-OH-midazolam from 
midazolam via CYP3A4/5. Differences in metabolic activity between undif-
ferentiated hiPSCs, 2D cultures, microspheroids, bioreactors and PHH were 
calculated using the unpaired, two-tailed t-test (hiPSC day 0 cultures and 
2D day 18 cultures: n=6; microspheroids day 18, bioreactors day 18 and adult 
PHH: n=3; median of biological replicates ± interquartile range). p<0.1 are 
given in the graphs. Values are normalized to the DNA content on day 18. 
n.d., not detected; d, day; hiPSCs, human induced pluripotent stem cells; 
PHH, primary human hepatocytes; MS, microspheroids; BR, bioreactors.
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To further confirm the present results, both basal and induced 
levels of CyP-activities, should be measured in future studies 
to judge the metabolic capabilities of HLC derivatives. Beside 
the 3D cultivation, an extended culture duration may increase 
the activity of CYP enzymes as described by Gieseck et al (29). 
In addition, repeated exposure to xenobiotics, mimicking the 
process of in vivo drug metabolizing maturation during the first 
years of childhood (52), may be another approach to further 
increase CyP activity in future models (17).
Normalization of the results. The cells in the different culture 
systems may behave differently, thereby influencing the 
parameters used for normalization. Hence, to allow a detailed 
comparison of different culture systems the method of normal-
ization needs to be considered carefully. Therefore, in the present 
study, the authors used two different methods for normalization. 
The initial cell number reflects the hiPSC number plated on 
2D culture plates or injected into the bioreactor. In both systems 
the hiPSCs were subsequently cultured for one or two days in 
mTeSR™1 medium, leading to the proliferation of the hiPSCs 
and therefore to an unknown cell number at the start of differ-
entiation. In addition, the cells still proliferated within the early 
differentiation phase as indicated by glucose consumption and 
lactate production. In contrast, for the microspheroid system 
the cell number reflects the number of differentiated cells at the 
start of the spheroid formation at day 11. At this differentiation 
stage, the cells have a low proliferation rate or have ceased to 
proliferate. Therefore, the values of energy metabolism and 
protein secretion obtained for the 2D cultures and bioreactors 
are probably overestimated, whereas for the microspheroid 
culture the values may represent more closely what is really 
expressed per cell. For the analysis of the CyP activities, which 
was performed only on day 18 of differentiation, the authors 
determined the DNA content at day 18 and used these values for 
normalization of CYP activities. This method is more accurate 
for day 18, but it does not reflect the cell number at the begin-
ning of culture and during the differentiation. In conclusion, 
both methods have their valid reasons for being used.
To conclude, the HLCs generated in the described culture 
systems still demonstrate an immature hepatic phenotype when 
compared to PHH and there have been recent expert work-
shops (53), which attempt to move the field forward. However, 
the 3D systems, particularly the bioreactor, seem to increase the 
developmental state of the cells as compared with 2D cultures, 
which may be due to the more physiological environment 
in complex 3D culture systems. It can be concluded that the 
choice of the culture system for HLCs depends primarily on the 
intended application: The bioreactor system provides an in vitro 
instrument for complex analyses, e.g., studies on the physiology 
and pathophysiology of cell differentiation, or on complex effects 
of xenobiotics. In contrast, microspheroids, due to their easy and 
cost-efficient handling, could be used for investigation of a higher 
number of drug candidates where a certain culture complexity is 
desired. Thus, both culture systems open the perspective for the 
development of improved in vitro hepatocyte models.
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